![Camurus, Audiocast with teleconference, Q2'24](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/18127181-e8fb-44ee-b085-a2fc6302f4df.png)
Log in to your Inderes Free account to see all free content on this page.
Camurus
676.5 SEK +4.08%7 investors are following this company
Camurus operates in biotechnology. The company runs as a research-based pharmaceutical company and develops and distributes products for the treatment of severe and chronic diseases. Diseases treated with the company's products include, for example, cancer, endocrine disorders, and patients with opioid dependence. Camurus runs development projects under its own auspices and in partnership with international pharmaceutical companies. The company is headquartered in Lund.
Revenue
-
EBIT %
-
P/E
86.95
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
CAMX
Daily low / high price
598 / 679.5
SEK
Market cap
39.67B SEK
Turnover
100.28M SEK
Volume
153K
Latest videos
Financial calendar
Interim report
16.07.2024
Interim report
07.11.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Sandberg Development AB | 38.0 % | 38.0 % |
Fjärde AP-fonden | 4.5 % | 4.5 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
![Camurus, Audiocast with teleconference, Q2'24](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/18127181-e8fb-44ee-b085-a2fc6302f4df.png)
Camurus AB: Camurus' Interim Report Second Quarter 2024
Camurus AB: Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Camurus AB: Change in number of shares and votes in Camurus
Camurus AB: New publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl
Camurus AB: Exercise of Camurus' employee stock options program 2021/2024
Camurus AB: Camurus' Board of Directors exercises authorization for repurchase of shares for the purpose of securing the company's commitments under the Performance Share Plan 2024/2027
Camurus AB: Camurus to present at Jefferies 2024 Healthcare Conference New York
Camurus AB: Camurus receives EMA acceptance of MAA filing for octreotide SC depot (CAM2029) for the treatment of acromegaly
Camurus AB: Resolutions at the annual general meeting 2024 in Camurus
![Camurus, Audiocast with teleconference, Q1, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/4f691bda-1f84-4756-a385-94b7afc6bb54.png)
Camurus, Audiocast with teleconference, Q1, 2024
Camurus AB: Camurus' Interim Report January-March 2024
Camurus AB: Notice of annual general meeting 2024 in Camurus (publ)
Camurus AB: Camurus Annual Report for 2023
Camurus AB: Camurus announces FDA acceptance of NDA submission for Oclaiz™ for treatment of acromegaly
![Camurus, Audiocast with teleconference, Q4, 2023](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/12c1d1bc-02ce-44cf-a8b5-e8666116a1fb.png)